Emergency Use of Targeted Osmotic Lysis for the Treatment of a Patient with Aggressive Late-Stage Squamous Cell Carcinoma of the Cervix

Authors

Harry J. Gould, LSU Health Sciences Center- New OrleansFollow
Paige R. Miller, Oleander Medical Technologies
Samantha Edenfield, LSU Health Sciences Center- New OrleansFollow
Kelly Jean Sherman, LSU Health Sciences Center- New OrleansFollow
Chad K. Brady, West Virginia University School of Medicine Morgantown
Dennis Paul, Oleander Medical Technologies

Document Type

Article

Publication Date

6-8-2021

Second Department

Pharmacology and Experimental therapeutics

Publication Title

Current Oncology

Abstract

Upregulation of voltage-gated sodium channels (VGSCs) and Na+/K+-ATPase (sodium pumps) is common across most malignant carcinomas. Targeted osmotic lysis (TOL) is a developing technology in which the concomitant stimulation of VGSCs and pharmacological blockade of sodium pumps causes rapid selective osmotic lysis of carcinoma cells. This treatment of cervical carcinoma is evidence that TOL is a safe, well-tolerated and effective treatment for aggressive advanced carcinomas that has the potential to extend life without compromising its quality. TOL is likely to have broad application for the treatment of advanced-stage carcinomas.

First Page

1

Last Page

8

PubMed ID

34201380

Volume

28

Issue

3

Publisher

MDPI

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Gould, Harry J.; Miller, Paige R.; Edenfield, Samantha; Sherman, Kelly Jean; Brady, Chad K.; and Paul, Dennis, "Emergency Use of Targeted Osmotic Lysis for the Treatment of a Patient with Aggressive Late-Stage Squamous Cell Carcinoma of the Cervix" (2021). School of Medicine Faculty Publications. 164.
https://digitalscholar.lsuhsc.edu/som_facpubs/164
10.3390/curroncol28030196

File Format

pdf

File Size

1498 KB